{"entity":{"id":"nct06784648","kind":"trial","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab, Ipilimumab in melanoma and uveal melanoma, run by BioInvent International AB, active and no longer recruiting.","summary":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06784648 by BioInvent International AB, with 35 participants planned, started 2024-12-11 and due to reach its primary completion in 2025-12-30. Interventions recorded: pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution). Conditions listed: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06784648","url":"https://clinicaltrials.gov/study/NCT06784648"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","ipilimumab"],"companies":["bioinvent-international"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06784648","phase":"1/2","setting":"An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma","sponsor":"BioInvent International AB","enrolled":35,"outcomes":[]},"route":"/trials/nct06784648/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"}]}}